Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / VIVO - Meridian Bioscience gets FDA EUA for Revogene SARS-CoV-2 molecular assay

VIVO - Meridian Bioscience gets FDA EUA for Revogene SARS-CoV-2 molecular assay

Meridian Bioscience Inc.
Meridian Bioscience (NASDAQ:VIVO) announces that their Revogene SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) by the U.S. FDA. Shares jump more than 7% premarket. The Revogene SARS-CoV-2 assay is a molecular diagnostic test for the qualitative detection of the SARS-CoV-2 virus, the causative agent of COVID-19. Meridian expects to begin shipping the product before the end of its fiscal first quarter, ending December 31, 2021.

For further details see:

Meridian Bioscience gets FDA EUA for Revogene SARS-CoV-2 molecular assay
Stock Information
Company Name: Meridian Bioscience Inc.
Stock Symbol: VIVO
Market: NASDAQ
Website: meridianbioscience.com
Menu
VIVO VIVO Quote VIVO Short VIVO News VIVO Articles VIVO Message Board
Get VIVO Alerts

News, Short Squeeze, Breakout and More Instantly...